Management of Antiplatelet Therapy in Femoral Artery Pseudoaneurysm Before Surgery

Introduction to Antiplatelet Therapy Management

• The American College of Surgeons and other medical societies recommend that clopidogrel should be discontinued 5 days before surgery for the femoral artery pseudoaneurysm, while aspirin should be continued throughout the perioperative period unless the bleeding risk is deemed extreme 1, 2

Rationale for Clopidogrel Discontinuation

• Clopidogrel must be stopped 5 days prior to vascular surgery because it irreversibly inhibits platelet aggregation for the lifetime of the platelet (7-10 days), and continuation significantly increases major bleeding, transfusion requirements, and surgical re-exploration rates 1

Rationale for Aspirin Continuation

• Aspirin should be maintained throughout the perioperative period to reduce the risk of perioperative cardiovascular events (myocardial infarction, stroke), as the thrombotic risk of discontinuation typically outweighs the bleeding risk in most surgical contexts 1, 2, 3
• The French Working Group on Perioperative Haemostasis recommends continuing aspirin for coronary artery surgery and most non-cardiac procedures, accepting a modest increase in bleeding to prevent catastrophic thrombotic events 1

Special Circumstances Requiring Modification

• If the patient has a drug-eluting coronary stent placed within the past 6-12 months, this creates an extreme thrombotic risk scenario that may warrant maintaining both aspirin and clopidogrel despite bleeding concerns, requiring urgent multidisciplinary consultation with cardiology 2
• If the patient has a bare-metal stent placed within 4-6 weeks, both agents should ideally be continued if at all possible, as stent thrombosis risk is maximal during this period 2

Common Pitfalls to Avoid

• Never discontinue both aspirin and clopidogrel simultaneously in patients with recent stent placement, as this dramatically increases stent thrombosis risk, which carries higher mortality than surgical bleeding 2
• Do not substitute antiplatelet therapy with heparin or low-molecular-weight heparin bridging, as anticoagulants do not protect against stent thrombosis and actually increase bleeding risk without providing adequate platelet inhibition 1, 2

Practical Algorithm

• Assess stent status: Determine if patient has coronary stents and timing of placement, and manage antiplatelet therapy accordingly 2
• If no recent stents (<6-12 months for drug-eluting, <4-6 weeks for bare-metal): Stop clopidogrel 5 days before surgery, continue aspirin 1, 2